pharma · No medical condition. · Generalized Myasthenia Gravis
Lacuna Pharma Pty Ltd
Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial
Phase 2 · small molecule · Acromegaly
Paltusotine (brand name PALSONIFY) is a small-molecule oral therapeutic developed by Lacuna Pharma Pty Ltd for the treatment of acromegaly, a rare endocrine disorder characterized by excessive growth hormone secretion. The drug is currently in Phase 2 development with an ongoing open-label, long-term extension study (A
Internal code CRN00808-05
Paltusotine (brand name PALSONIFY) is a small-molecule oral therapeutic developed by Lacuna Pharma Pty Ltd for the treatment of acromegaly, a rare endocrine disorder characterized by excessive growth hormone secretion. The drug is currently in Phase 2 development with an ongoing open-label, long-term extension study (ACROBAT ADVANCE) evaluating safety and efficacy in acromegaly patients. Paltusotine has achieved regulatory approval in the European Union as of April 23, 2026, marketed by Crinetics Pharmaceuticals Europe GmbH under EMA product number EMEA/H/C/006636. The mechanism of action and specific molecular target remain undisclosed in available sources. Lacuna Pharma's development strategy focuses on establishing long-term safety and efficacy data through extension studies, positioning paltusotine within a competitive acromegaly treatment landscape that includes established therapies such as SOMAVERT (pegvisomant), SIGNIFOR (pasireotide), and SOGROYA (somapacitan).
Acromegaly is a rare but serious endocrine disorder affecting approximately 40–70 individuals per million population, characterized by excessive growth hormone and insulin-like growth factor-1 (IGF-1) production. The disease causes significant morbidity including cardiovascular complications, arthropathy, metabolic dysfunction, and reduced life expectancy if untreated. Current therapeutic options include somatostatin receptor ligands, growth hormone receptor antagonists, and dopamine agonists, yet treatment remains challenging due to variable patient response, tolerability issues, and the need for frequent dosing or injections in many cases. An oral small-molecule therapeutic addresses a key unmet need for improved convenience and potentially enhanced patient adherence. The competitive landscape includes multiple approved agents targeting different pathways (GH receptor antagonism, somatostatin signaling, dopamine agonism), indicating a market with established demand but room for differentiation. Paltusotine's European approval signals regulatory confidence in its safety and efficacy profile, potentially expanding treatment options for patients with inadequate response to or intolerance of existing therapies. The commercial significance is substantial given the chronic nature of acromegaly and the premium pricing typical for rare disease therapeutics.
Drug Class: Systemic hormonal preparation (ATC H01)
Modality: Small-molecule oral tablet
Mechanism of Action: Not yet disclosed
Molecular Target: Not yet disclosed
Route of Administration: Oral (tablet formulation)
Indication: Acromegaly
Related Therapies: Paltusotine competes within the acromegaly treatment class alongside somatostatin receptor ligands (SIGNIFOR, SOGROYA), growth hormone receptor antagonists (SOMAVERT), and other endocrine-active agents. The specific mechanism distinguishing paltusotine from competitors is not yet disclosed.
Regulatory Status: Approved in the European Union (April 23, 2026); Phase 2 development ongoing in other regions
Patent Status: Not yet disclosed
Also known as: Growth hormone excess, pituitary giant, somatotroph adenoma
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Acromegaly is an acquired disorder related to excessive production of growth hormone (GH) and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations.
ClinicalTrials.gov lists 9 registered studies for Growth Hormone (AACT aggregate).
Phase breakdown: NA (6), PHASE3 (2), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0019933), Orphanet — acromegaly, NCT00562796, NCT00966134, NCT01158612, NCT01540773, NCT04079010, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
ACROBAT ADVANCE Long-Term Extension Study
Open-label, long-term extension study evaluating safety and efficacy of paltusotine (CRN00808) in subjects with acromegaly; currently active.
EMA Approval
Paltusotine (PALSONIFY) approved by the European Medicines Agency under centralized procedure (EMEA/H/C/006636); marketed by Crinetics Pharmaceuticals Europe GmbH.
The acromegaly treatment market includes multiple approved therapeutic classes. SOMAVERT (pegvisomant, Pfizer) is a growth hormone receptor antagonist representing a distinct mechanism from somatostatin-based approaches. SIGNIFOR and SOGROYA are somatostatin receptor ligands with different pharmacokinetic profiles and dosing schedules. NGENLA (lonapegsomatropin, Pfizer) and SKYTROFA (lonapegsomatropin, Ascendis Pharma) represent long-acting growth hormone formulations. INCRELEX (mecasermin, listed as a competitor from Lacuna Pharma) is an IGF-1 replacement therapy. THYROGEN (thyrotropin alfa, Sanofi), CETROTIDE (cetrorelix, Merck KGaA), and ARX GANIRELIX (ganirelix, Alphapharm) serve specialized roles in endocrine management. ORGOVYX and YSELTY are also listed as approved competitors but their specific roles in acromegaly management are not detailed in available sources. Paltusotine's oral small-molecule formulation differentiates it from injectable and long-acting depot formulations, potentially offering improved convenience and patient adherence. However, the undisclosed mechanism of action limits detailed competitive positioning at this time.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| INCRELEX | Lacuna Pharma Pty Ltd | — | approved |
| ORGOVYX | — | — | approved |
| THYROGEN | Sanofi-aventis Healthcare Pty Ltd | — | approved |
| SOMAVERT | Pfizer Australia Pty Ltd | — | approved |
| GENOTROPIN GOQUICK | Pfizer Australia Pty Ltd | — | approved |
| SIGNIFOR | — | — | approved |
| SOGROYA | — | — | approved |
| ARX GANIRELIX | Alphapharm Pty Ltd | — | approved |
| NGENLA | Pfizer Australia Pty Ltd | — | approved |
| CETROTIDE | Merck KGaA, Darmstadt, Germany | — | approved |
| YSELTY | — | — | approved |
| SKYTROFA (PREVIOUSLY LONAPEGSOMATROPIN ASCENDIS PHARMA) | — | — | approved |
| PEGVISOMANT | — | Growth hormone receptor antagonist | Approved |
| PASIREOTIDE PAMOATE | — | Somatostatin receptor 2 agonist | Approved |
| OCTREOTIDE ACETATE | — | Somatostatin receptor agonist | Approved |
| LANREOTIDE ACETATE | — | Somatostatin receptor 2 agonist | Approved |
| BROMOCRIPTINE MESYLATE | — | D2-like dopamine receptor agonist | Approved |
| PASIREOTIDE | — | Somatostatin receptor 5 agonist | Phase 3 |
| PALTUSOTINE | — | Somatostatin receptor 2 agonist | Phase 3 |
| OCTREOTIDE | — | Somatostatin receptor agonist | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
European Union: Paltusotine (PALSONIFY) received centralized approval on April 23, 2026, under EMA product number EMEA/H/C/006636. Marketing authorization holder is Crinetics Pharmaceuticals Europe GmbH. Full EPAR (European Public Assessment Report) available at https://www.ema.europa.eu/en/medicines/human/EPAR/palsonify.
United States FDA: Regulatory status not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
The program remains in Phase 2 development in jurisdictions outside the EU, with ongoing long-term extension studies generating additional safety and efficacy data to support potential future regulatory submissions.
Paltusotine is an oral small-molecule therapeutic approved for the treatment of acromegaly, a rare endocrine disorder characterized by excessive growth hormone secretion.
Yes, paltusotine (brand name PALSONIFY) was approved by the European Medicines Agency on April 23, 2026. Regulatory status in other regions including the US, Japan, and China is not yet disclosed.
Paltusotine is developed by Lacuna Pharma Pty Ltd. In the European Union, the marketing authorization holder is Crinetics Pharmaceuticals Europe GmbH.
The specific mechanism of action of paltusotine has not yet been disclosed in available sources.
The molecular target of paltusotine has not yet been disclosed.
The internal development code for paltusotine is CRN00808-05.
An open-label, long-term extension study called ACROBAT ADVANCE (NCT 2024-511921-75-00) is currently active, evaluating the safety and efficacy of paltusotine in subjects with acromegaly.
Paltusotine is in Phase 2 development in most regions, with an ongoing long-term extension study. It has achieved regulatory approval in the European Union.
Paltusotine is administered as an oral tablet, offering a convenient non-injectable formulation compared to many competing acromegaly therapies.
Competitors in the acromegaly market include SOMAVERT (pegvisomant), SIGNIFOR (pasireotide), SOGROYA (somapacitan), NGENLA (lonapegsomatropin), SKYTROFA (lonapegsomatropin), and other growth hormone-modulating agents.
Acromegaly is a rare endocrine disorder caused by excessive growth hormone and IGF-1 production, leading to abnormal growth, cardiovascular complications, and metabolic dysfunction if untreated.
The EMA product number for PALSONIFY (paltusotine) is EMEA/H/C/006636.
Paltusotine (PALSONIFY) was approved by the European Medicines Agency on April 23, 2026.
Paltusotine is classified as a systemic hormonal preparation (ATC code H01).
No partner or co-developer is listed for paltusotine; it is being developed by Lacuna Pharma Pty Ltd.
ACROBAT ADVANCE is an open-label, long-term extension study evaluating the safety and efficacy of paltusotine (CRN00808) in subjects with acromegaly; it is currently active.
Paltusotine tablets, Paltusotine tablets → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Lacuna Pharma's EMA approval of paltusotine in April 2026 represents a significant regulatory milestone validating the oral small-molecule approach to acromegaly management. The ongoing Phase 2 ACROBAT ADVANCE extension study suggests the company is building a comprehensive safety database to support potential label expansions and regulatory submissions in additional markets. The undisclosed mechanism of action limits competitive analysis but may indicate a novel target or pathway differentiation.
Competitive Implications: Paltusotine enters a mature acromegaly market with established standard-of-care options. Its oral formulation addresses a key convenience advantage over injectable competitors (SOMAVERT, SIGNIFOR, SOGROYA, NGENLA, SKYTROFA), potentially capturing patients with injection reluctance or adherence challenges. However, competitive efficacy, tolerability, and pharmacokinetic profiles relative to existing agents remain undisclosed.
Future Catalysts: Key upcoming milestones include completion of the ACROBAT ADVANCE extension study, potential regulatory submissions in the US (FDA) and other major markets, and publication of long-term safety and efficacy data. Label expansion opportunities (e.g., combination therapy, specific patient subpopulations) may emerge from ongoing trials.
Expected Milestones: Phase 2 data readouts, regulatory submissions in non-EU markets, and potential Phase 3 initiation or accelerated pathways remain to be disclosed.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.